Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2184 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-11

Study Completion Date

2018-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza

NCT02954354

Influenza

COMPLETED PHASE3

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

NCT03684044

Influenza

COMPLETED PHASE3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

NCT03629184

Influenza

COMPLETED PHASE3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms

NCT06774859

Influenza

COMPLETED PHASE3

Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting

NCT06762587

Influenza Influenza Prophylaxis Nosocomial Infection

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baloxavir Marboxil

Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of \< 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.

Group Type EXPERIMENTAL

Baloxavir Marboxil

Intervention Type DRUG

Tablets taken orally

Placebo to Oseltamivir

Intervention Type DRUG

Matching placebo capsules taken orally

Oseltamivir

Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.

Group Type ACTIVE_COMPARATOR

Placebo to Baloxavir Marboxil

Intervention Type DRUG

Matching tablets taken orally

Oseltamivir

Intervention Type DRUG

Capsules taken orally

Placebo

Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.

Group Type PLACEBO_COMPARATOR

Placebo to Baloxavir Marboxil

Intervention Type DRUG

Matching tablets taken orally

Placebo to Oseltamivir

Intervention Type DRUG

Matching placebo capsules taken orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baloxavir Marboxil

Tablets taken orally

Intervention Type DRUG

Placebo to Baloxavir Marboxil

Matching tablets taken orally

Intervention Type DRUG

Oseltamivir

Capsules taken orally

Intervention Type DRUG

Placebo to Oseltamivir

Matching placebo capsules taken orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

S-033188 Xofluza® Tamiflu®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients or their legal guardians who provide written informed consent to participate in the study on a voluntary basis. For adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements.
2. Male or female patients ≥ 12 years at the time of signing the informed consent/assent form.
3. Patients with a diagnosis of influenza confirmed by all of the following:

1. Fever ≥ 38ºC (axillary) during the predose examinations or within the 4 hours prior if antipyretics were taken
3. At least 1 each of the following general and respiratory symptoms associated with influenza is present with a severity of moderate or greater:

i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)
4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:

1. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
2. Time when the patient experiences at least 1 new general or respiratory symptom
5. If a women of childbearing potential, agrees to use a highly effective method of contraception for 3 months after the first dose of study drug

1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)
2. Endocrine disorders (including diabetes mellitus)
3. Residents of long-term care facilities (eg, nursing homes)
4. Compromised immune system (including patients receiving corticosteroids not exceeding 20 mg of prednisolone or equivalent, and patients being treated for human immunodeficiency virus \[HIV\] infection with a CD4 count \> 350 cells/mm³ within the last 6 months)
5. Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy \[seizure disorders\], stroke, muscular dystrophy, or spinal cord injury)
6. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms
7. Adults aged ≥ 65 years
8. American Indians and Alaskan Natives
9. Blood disorders (such as sickle cell disease)
10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
11. Morbid obesity (body mass index ≥ 40 kg/m²)
12. Women who are within 2 weeks postpartum and are not breastfeeding

Exclusion Criteria

1. Patients with severe influenza virus infection requiring inpatient treatment.
2. Patients with known allergy to oseltamivir (Tamiflu®).
3. Patients unable to swallow tablets or capsules.
4. Patients who have previously received baloxavir marboxil.
5. Patients weighing ≤ 40 kg.
6. Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.
7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:

1. Postmenopausal women (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test)
2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
8. Patients with concurrent infections at the predose examinations requiring systemic antimicrobial therapy.
9. Patients with liver disease associated with hepatic impairment.
10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).
11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months.
12. Patients with immunosuppression following organ or bone marrow transplants.
13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic corticosteroids.
14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to the predose examinations.
15. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
16. Patients with known creatinine clearance ≤ 60 mL/min.
17. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No